MORPHOSYS ANNOUNCES AGREEMENT WITH JAPANESE PHARMACEUTICAL COMPANY SHIONOGI
MorphoSys AG (Frankfurt:MOR) and Shionogi & Co., Ltd. announced today that they have signed a three-year license agreement on the use of MorphoSys's HuCAL(R) technology. Under the terms of the agreement, MorphoSys grants Shionogi access to its HuCAL GOLD(R) antibody library for use in Shionogi's pharmaceutical drug discovery programs. In return, MorphoSys stands to receive an up-front payment and annual user fees during the life span of the agreement. Further financial details were not disclosed.